Preclinical Ophthalmic Research
As a multidisciplinary contract research organization, Toxikon is focused on evaluating the safety and toxicity of biologics, pharmaceuticals and medical devices. One of Toxikon’s specialties is conducting studies focused on the treatment of ocular diseases. Our experienced study directors will provide you with the expertise in ophthalmology models and endpoints for your ocular drug program.
Ophthalmic Development Capabilities
While our reputation has been built on our vast toxicology and chemistry experience,Toxikon’s Ocular Program capabilities include:
- Intra-vitreal injections, stereotaxic surgery
- Aesthesiometry, tonometry, pupilometry; and electroretinography (ERG)
- Slit-Lamp exams and Draize and McDonald-Shadduck scoring systems Direct and indirect ophthalmoscopy
- Anterior/posterior segment and fundus photography
- Ocular tissue dissection, distribution and PK/PD/ADME
- Retina/choroid flat-whole mounting, confocal microscopy, and RGC quantitation
- Ocular histology/pathology and clinical support
- Stereo and fluorescent microscopy
- Optic nerve damage assessment
- Specialized surgeries (e.g. episcleral vein injections to induce elevated IOP)
These studies in small and large animal models, include acute irritation, ocular distribution (PK/PD), acute and repeat dose toxicity, implantation, drug screening and drug efficacy. We can also customize studies for targeted therapeutics, such as dry eye and corneal wound healing, inflammation and uveitis, neovascularization and age-related macular degeneration, glaucoma and neuroprotection.
As part of our extensive custom research and testing portfolio for ophthalmic drug discovery, we offer a variety of preclinical services, including the screening of neuroprotective compounds and creation of animal models for glaucoma research. Our scientists are experts in the field, and their work is published widely. We invite you to speak with them at upcoming conferences and to see samples of their work.